Exemestane

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Exemestane (ncit:C1097)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Exemestane
Sensitivity (+) ER positive Invasive Breast Carcinoma Exemestane
Sensitivity (+) PR positive Invasive Breast Carcinoma Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
Sensitivity (+) ER positive Invasive Breast Carcinoma Exemestane